InMed Pharmaceuticals Inc. (INM) Income Statement
INM FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsINM revenue and net income
Where INM's revenue goes
FY2026Each bar shows an amount and its share of revenue. INM kept −0.4% of revenue as net income.
INM profit margins
INM growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +64,167.3% | — | — | — |
| Gross profit | +41,494.3% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
INM quarterly EPS vs estimates
Next report: November 5, 2026.
INM income statement
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | $3.18B | $4.9M |
| Cost of revenue | $2.47B | $3.2M |
| Gross profit | $709.8M | $1.7M |
| Research & development | $15.1M | $2.9M |
| Sales, general & admin | $1.88B | $6.6M |
| Total operating expenses | $9.2M | $9.6M |
| Operating income | −$9.9M | −$7.9M |
| Interest income | $244,971 | $155,882 |
| Interest expense | $10,700 | $373,105 |
| Income before taxes | −$11.4M | −$8.2M |
| Net income | −$12.6M | −$8.2M |
| EBITDA | −$9.2M | −$7.3M |
| EPS (diluted) | −$3.12 | −$7.00 |
| Gross margin | 22.3% | 34.5% |
| Operating margin | −0.3% | −160.2% |
| Net margin | −0.4% | −165.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.06B | $659.8M | $1.1M | $1.1M | $1.8M | $1.3M | $1.1M |
| Cost of revenue | $1.75B | $134,656 | $1.1M | $716,962 | $991,692 | $1.1M | $650,813 |
| Gross profit | $306.9M | −$134,656 | $35,915 | $403,159 | $785,466 | $175,625 | $460,894 |
| Research & development | $567.9M | $1.0M | $865,314 | $581,612 | $153,537 | $909,653 | $1.1M |
| Sales, general & admin | $1.87B | $1.7M | $2.1M | $1.5M | $3.1M | $1.3M | $1.6M |
| Total operating expenses | $3.0M | $2.8M | $2.9M | $2.2M | $3.2M | $2.3M | $2.7M |
| Operating income | −$3.2M | −$2.8M | −$2.9M | −$1.8M | −$2.4M | −$2.1M | −$2.2M |
| Interest income | $29,057 | $47,770 | $74,379 | $93,765 | $51,687 | $16,565 | $30,536 |
| Interest expense | $10,700 | $0 | $0 | — | $20,000 | $0 | $351,549 |
| Income before taxes | −$4.8M | −$2.8M | −$2.8M | −$1.7M | −$2.4M | −$2.1M | −$2.6M |
| Net income | −$5.1M | −$3.0M | −$2.8M | −$1.7M | −$2.4M | −$2.1M | −$2.6M |
| EBITDA | −$3.0M | −$2.7M | −$2.6M | −$1.6M | −$2.4M | −$2.0M | −$2.1M |
| EPS (diluted) | −$1.43 | −$0.73 | −$0.51 | −$0.44 | −$1.20 | −$1.94 | −$3.64 |
| Gross margin | 14.9% | −0.0% | 3.2% | 36.0% | 44.2% | 13.9% | 41.5% |
| Operating margin | −0.2% | −0.4% | −258.6% | −157.5% | −137.1% | −167.7% | −198.5% |
| Net margin | −0.2% | −0.4% | −247.3% | −154.2% | −137.1% | −168.1% | −231.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in INM's financial statements (latest annual report filed September 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
INM financial results
In fiscal year 2026 (ended June 30, 2026), InMed Pharmaceuticals reported revenue of $3.2 billion, up 64,167.3% from the year before. It had a net loss of $12.6 million, a net profit margin of −0.4%. Diluted earnings per share came to −$3.12.
See the INM stock overview for the latest quote and news, or the INM chart for price history and technical indicators.
INM income statement FAQ
What is InMed Pharmaceuticals's annual revenue?
InMed Pharmaceuticals reported total revenue of $3.2 billion for fiscal year 2026, which ended on June 30, 2026. That was up 64,167.3% from $4.9 million the previous year.
Is InMed Pharmaceuticals profitable?
No. InMed Pharmaceuticals reported a net loss of $12.6 million in fiscal 2026, a net profit margin of −0.4%; its operating margin was −0.3%.
What is InMed Pharmaceuticals's gross margin?
InMed Pharmaceuticals's gross margin was 22.3% in fiscal 2026: for every $100 of revenue, InMed Pharmaceuticals kept $22 after the direct cost of its products and services.
How much does InMed Pharmaceuticals spend on research and development?
InMed Pharmaceuticals spent $15.1 million on research and development in fiscal 2026, 0.5% of revenue.
What are InMed Pharmaceuticals's earnings per share?
InMed Pharmaceuticals earned $-3.12 per diluted share in fiscal 2026, compared with $-7.00 a year earlier.
When will InMed Pharmaceuticals report its next earnings?
InMed Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does InMed Pharmaceuticals's fiscal year end?
InMed Pharmaceuticals's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on September 9, 2026.